Anabolic steroids and cardiovascular risk: A national population-based cohort study

Drug and Alcohol Dependence

Volumn 152, Issue , 2015, Pages 87-92

  Thiblin, Ingemar ^a   Garmo, Hans ^b   Garle, Mats ^c   Holmberg, Lars ^a,b   Byberg, Liisa ^a   Michaëlsson, Karl ^a   Gedeborg, Rolf ^a,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Anabolic androgenic steroids; Cardiac disease; Injury; Morbidity; Mortality; Psychiatric disease

Indexed keywords

ANABOLIC AGENT; STEROID;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COR PULMONALE; ENDOCARDITIS; ESOPHAGUS VARICES; FEMALE; HAZARD RATIO; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HOMICIDE; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; MORTALITY; MYOCARDITIS; PERICARDITIS; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; REGISTER; SUICIDE; VALVULAR HEART DISEASE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHEMICALLY INDUCED; EDUCATIONAL STATUS; FOLLOW UP; MIDDLE AGED; PREMATURE MORTALITY; SOCIOECONOMICS; SWEDEN; YOUNG ADULT;

ADOLESCENT; ADULT; ANABOLIC AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; EDUCATIONAL STATUS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY, PREMATURE; REGISTRIES; SOCIOECONOMIC FACTORS; STEROIDS; SWEDEN; YOUNG ADULT;

EID: 84930476961     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.04.013     Document Type: Article

References (47)

1. Angell P., Chester N., Green D., Somauroo J., Whyte G., George K. Anabolic steroids and cardiovascular risk. Sports Med. 2012, 42:119-134.
2. Arvary D., Pope H.G. Anabolic-androgenic steroids as a gateway to opioid dependence. N. Engl. J. Med. 2000, 342:1532.
3. Baggish A.L., Weiner R.B., Kanayama g., Hudson J.L., Picard M.H., Hutter A.M., Pope H.G. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ. Heart Fail. 2010, 3:472-476.
4. Basaria S., Coviello A.D., Travison T.G., Storer T.W., Farwell W.R., Jette A.M., Eder R., Tennstedt S., Ulloor J., Zhang A., Choong K., Lakshman K.M., et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 2010, 363:109-122.
5. Beaver K.M., Vaughn M.G., Dellisi M., Wright J.P. Anabolic-androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the United States. Am. J. Public Health 2008, 98:2185-2187.
6. Statistical Methods in Cancer Research: The Design and Analysis of Cohort Studies 1987, International Agency for Research on Cancer, Lyon, France. N.E. Breslow, N.E. Day (Eds.).
7. Brower K.J., Blow F.C., Eliopulos G.A., Beresford T.P. Anabolic androgenic steroids and suicide. Am. J. Psychiatry 1989, 146:1075.
8. Copeland J., Peters R., Dillon P. Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug Alcohol Depend. 2000, 60:91-96.
9. Dodge T., Hoagland M.F. The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend. 2011, 114:100-109.
10. Dunn M., White V. The epidemiology of anabolic-androgenic steroid use among Australian secondary school students. J. Sci. Med. 2011, 14:10-14.
11. Far H.R., Ågren G., Thiblin I. Cardiac hypertrophy in deceased users of anabolic androgenic steroids: an investigation of autopsy findings. Cardiovasc. Pathol. 2012, 21:312-316.
12. Finkle W., Greenland S., Ridgeway G.K., Adams J.L., Frasco M.A., Cook M.B., Fraumeni J.F., Hoover R.N. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 2014, 9:e85805. 10.1371/journal.pone.0085805.
13. Garevik N., Rane A. Dual use of anabolic-androgenic steroids and narcotics in Sweden. Drug Alcohol Depend. 2010, 109:144-146.
14. Hajimoradi B., Kazerani H. Echocardiographic findings in power athletes abusing anabolic androgenic steroids. Asian J. Sports Med. 2013, 4:10-14.
15. Hartgens F., Cheriex E.C., Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int. J. Sports Med. 2003, 24:344-351.
16. Jacobs D.R., Adachi H., Mulder I., Kromhout D., Menotti A., Nissinen A., Blackburn H. Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study. Arch. Intern. Med. 1999, 159:733-740.
17. Kanayama G., Hudson J.I., Pope H.G. Illicit anabolic-androgenic steroid use. Horm. Behav. 2010, 58:111-121.
18. Kindlund A., Isacson D., Berglund L., Nyberg F. Doping among high school students in Uppsala, Sweden: a presentation of the attitudes, distribution, side effects, and extent of use. Scand. J. Soc. Med. 1998, 26:71-74.
19. Klotz F., Petersson A., Hoffman O., Thilblin I. The significance of anabolic androgenic steroids in a Swedish prison population. Compre. Psychiatry 2010, 51:312-318.
20. Klotz F., Petersson A., Isacson D., Thilblin I. Violent crime and substance abuse: a medico-legal comparison between deceased users of anabolic androgenic steroids and abusers of illicit drugs. Forensic Sci. Int. 2007, 173:57-63.
21. Ludvigsson J.F., Andersson E., Ekbom A., Feychting M., Kim J.L., Reuterwall C., Heurgren M., Olausson P.O. External review and validation of the Swedish national inpatient register. BMC Public Health 2011, 11:450.
22. Ludvigsson J.F., Otterblad-Olausson P., Pettersson B.U., Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur. J. Epidemiol. 2009, 24:659-667.
23. Lundholm L., Kall K., Wallin S., Thiblin I. Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug Alcohol Depend. 2010, 111:222-226.
24. Maior A.S., Carvalho A.R., Marques-Neto S.R., Menezes P., Soares P.P., Nascimento J.H. Cardiac autonomic dysfunction in anabolic steroid users. Scand. J. Med. Sci. Sports 2013, 23:548-555.
25. Maravelias C., Dona A., Stefanidou M., Spillopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol. Lett. 2005, 158:167-175.
26. Mattila V.M., Rimpela A., Jormanainen V., Sahi T., Pihlajamaki H. Anabolic-androgenic steroid use among young Finnish males. Scand. J. Med. Sci. Sports 2010, 20:330-335.
27. McCabe S.E., Brower K.J., West B.T., Nelson T.F., Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend. 2007, 90:243-251.
28. MMWR Recomm.Rep. Recommended framework for presenting injury mortality data. MMWR Recomm. Rep. 1997, 46:1-30.
29. Montisci M., el Mazloum R., Checchetto G., Terranova C., Ferrara S.D., Thiene G., Basso C. Anabolic androgenic steroid abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci. Int. 2012, 17:e13-e18.
30. Palatini P., Giada F., Garavelli G., Sinisi F., Mario L., Michieletto M., Baldo-Enzi G. Cardiovascular effects of anabolic steroids in weight-trained subjects. J. Clin. Pharmacol. 1996, 36:1132-1140.
31. Petersson A., Bengtsson J., Voltaire-Carlsson A., Thiblin I. Substance abusers' motives for using anabolic androgenic steroids. Drug Alcohol Depend. 2010, 111:170-172.
32. Petersson A., Garle M., Granath F., Thiblin I. Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care. A controlled retrospective cohort study. Drug Alcohol Depend. 2006, 81:215-220.
33. Petersson A., Garle M., Holmgren P., Druid H., Krantz P., Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006, 81:241-249.
34. Pope H.G., Katz D.L. Homicide and near-homicide by anabolic steroid users. J. Clin. Psychiatry 1990, 51:28-31.
35. Quaglio G., Fornasiero A., Mezzelani P., Moreschini S., Lugoboni F., Lechi A. Anabolic steroids: dependence and complications of chronic use. Intern. Emerg. Med. 2009, 4:289-296.
36. Skarberg K., Nyberg F., Engstrom I. I. Is there an association between the use of anabolic-androgenic steroids and criminality?. Eur. Addict. Res. 2010, 16:213-219.
37. Skarberg K., Nyberg F., Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur. Addict. Res. 2009, 15:99-106.
38. Sullivan M.L., Martinez C.M., Gennis P., Gallagher E.J. The cardiac toxicity of anabolic steroids. Prog. Cardiovasc. Dis. 1998, 41:1-15.
39. Thiblin I., Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam. Clin. Pharmacol. 2005, 19:27-44.
40. Thiblin I., Runeson B., Rajs J. Anabolic androgenic steroids and suicide. Ann. Clin. Psychiatry 1999, 11:223-231.
41. Thiblin I., Lindquist O., Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J. Forensic Sci. 2000, 45:16-23.
42. Thompson P.D., Sadaniantz A., Cullinane E.M., Bodziony K.S., Catlin D.H., Torek-Both G., Douglas P.S. Left ventricular function is not impaired in weight-lifters who use anabolic steroids. J. Am. Coll. Cardiol. 1992, 19:278-282.
43. Vanberg P., Atar D. Androgenic anabolic steroid abuse and the cardiovascular system. Handb. Exp. Pharmacol. 2010, 195:411-457.
44. Vigen R., O'Donnell C.I., Baron A.E., Grunwald G.K., Maddox T.M., Bradley S.M., Bargawi A., Woning G., Wierman M.E., Plomondon M.E., Rumsfeld J.S., Ho P.M. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013, 310:1829-1836.
45. Wikstrom L., Pedersen W. Use of anabolic-androgenic steroids in adolescence: winning, looking good or being bad?. J. Stud. Alcohol 2001, 62:5-13.
46. Woerdeman J., de Ronde W. Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting. Expert Opin. Invest. Drugs 2011, 20:87-97.
47. Zuliani U., Bernardini B., Catapano A., Campana M., Cerioli G., Spattinni M. Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders. Int. J. Sports Med. 1989, 10:62-66.